Science Explorer Back to mapMap

Most cited papers from Vifor Pharma (United States)

What are the most cited papers from Vifor Pharma (United States)?

The most cited paper from Vifor Pharma (United States) is "Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes" (Allan J. Collins, Bertram Pitt, Nancy L. Reaven et al., 2017), with 411 citations. Next come "Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial" (375) and "Poly(ortho esters): synthesis, characterization, properties and uses" (370).

Showing 50 of 60 papers. Every paper with more than 26 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes Allan J. Collins, Bertram Pitt, Nancy L. Reaven et al. · American Journal of Nephrology Open access 2017 411
2 Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial Rajiv Agarwal, Patrick Rossignol, Alain Romero et al. · The Lancet Open access 15 Sep 2019 375
3 Poly(ortho esters): synthesis, characterization, properties and uses Jorge Heller, John Barr, Steven Y Ng et al. · Advanced Drug Delivery Reviews Review Oct 2002 370
4 Microneedle-Based Vaccines Mark R. Prausnitz, John A. Mikszta, Michel Cormier et al. · Current topics in microbiology and immunology Book chapterOpen access 2009 314
5 Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines Chun Wang, Qing Ge, David Tsai Ting et al. · Nature Materials 15 Feb 2004 263
6 Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis Evan S. Dellon, A M Irani, Martin Hill et al. · Alimentary Pharmacology & Therapeutics Open access 9 Jul 2013 174
7 Design of an injectable system based on bioerodible polyanhydride microspheres for sustained drug delivery Matt J. Kipper, Elizabeth Shen, Amy S. Determan et al. · Biomaterials 26 Aug 2002 158
8 Recurrent Lower Urinary Tract Infections Have a Detrimental Effect on Patient Quality of Life: a Prospective, Observational Study Julien Renard, Stefania Ballarini, Teresa Mascarenhas et al. · Infectious Diseases and Therapy Open access 17 Dec 2014 156
9 NEUROGENIC INFLAMMATION AND MIGRAINE: IMPLICATIONS FOR THE THERAPEUTICS Stephen J. Peroutka · Molecular Interventions Oct 2005 140
10 Maternal Omega-3 Nutrition, Placental Transfer and Fetal Brain Development in Gestational Diabetes and Preeclampsia Prasad P. Devarshi, Ryan W. Grant, Chioma J. Ikonte et al. · Nutrients Open access 18 May 2019 132
11 Uric acid is closely linked to vascular nitric oxide activity Andrew J. Maxwell, Kristen A Bruinsma · Journal of the American College of Cardiology Open access Dec 2001 119
12 Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations Jennifer S. Gewandter et al. · Pain Open access 24 May 2014 111
13 Hepatotoxic Potential of Therapeutic Oligonucleotides Can Be Predicted from Their Sequence and Modification Pattern Peter Hagedorn, Victor Yakimov, Søren Ottosen et al. · Nucleic Acid Therapeutics Open access 16 Aug 2013 104
14 Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients Rudolf Peter Wuthrich, Michel Chonchol, Adrian Constantin Covic et al. · Clinical Journal of the American Society of Nephrology Open access 3 Nov 2012 89
15 Significance of endangered and threatened plant natural products in the control of human disease Mohamed A. Ibrahim, MinKyun Na, Joonseok Oh et al. · Proceedings of the National Academy of Sciences Open access 30 Sep 2013 87
16 Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies Riccardo Riccardi, Daniela Meco, Tina Colombo et al. · Cancer Chemotherapy and Pharmacology Aug 2003 76
17 Randomized trial of a medical food for the dietary management of chronic, stable angina Andrew J. Maxwell, Michael P. Zapien, Greg L. Pearce et al. · Journal of the American College of Cardiology Open access 2002 73
18 The future of cancer immunotherapy: DNA vaccines leading the way Aanshi J. Pandya, Yesha B. Shah, Nirjari R. Kothari et al. · Medical Oncology Open access 9 Jun 2023 70
19 Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension Stacie A. Hudgens, Christopher J. Evans, Elaine Phillips et al. · Journal of Patient-Reported Outcomes Open access 11 Aug 2017 69
20 Iron Deficiency Generates Secondary Thrombocytosis and Platelet Activation in IBD Stefanie Kulnigg‐Dabsch, Werner Schmid, Stefanie M. Howaldt et al. · Inflammatory Bowel Diseases Open access 3 May 2013 68
21 Quenching protein dynamics interferes with HIV capsid maturation Mingzhang Wang, Caitlin M. Quinn, Juan R. Perilla et al. · Nature Communications Open access 20 Nov 2017 64
22 The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose Felix Funk, Peter R. Ryle, Camillo Canclini et al. · Arzneimittelforschung 21 Dec 2011 64
23 Population‐Based Exposure‐Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis Honghui Zhou, Chuanpu Hu, Yaowei Zhu et al. · The Journal of Clinical Pharmacology 23 Nov 2009 64
24 Long-Term Effects of Patiromer for Hyperkalaemia Treatment in Patients with Mild Heart Failure and Diabetic Nephropathy on Angiotensin-Converting Enzymes/Angiotensin Receptor Blockers: Results from AMETHYST-DN Bertram Pitt, George L. Bakris, Matthew R. Weir et al. · ESC Heart Failure Open access 16 May 2018 59
25 Evaluation of an Individualized Dose Titration Regimen of Patiromer to Prevent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease Bertram Pitt, David A. Bushinsky, Dalane W. Kitzman et al. · ESC Heart Failure Open access 25 Jan 2018 58
26 Safety and Efficacy of Iron(III)-hydroxide Polymaltose Complex Peter Geisser · Arzneimittelforschung 21 Dec 2011 58
27 Endothelial Dysfunction in Hypercholesterolemia is Reversed by a Nutritional Product Designed to Enhance Nitric Oxide Activity Andrew J. Maxwell, Barbara E. Anderson, Michael P. Zapien et al. · Cardiovascular Drugs and Therapy Mar 2000 57
28 Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( AMBER ): Results in the Pre-Specified Subgroup with Heart Failure Patrick Rossignol, Bryan Williams, Martha R. Mayo et al. · European Journal of Heart Failure Open access 25 May 2020 54
29 Use of intravenous iron supplementation in chronic kidney disease: an update. Iain C. Macdougall, Peter Geisser · PubMed Open access 2013 54
30 Mutations in the rpoB Gene of Rifampin-Resistant Mycobacterium tuberculosis Isolates in Spain and Their Rapid Detection by PCR–Enzyme-Linked Immunosorbent Assay Lucia Garcia, Mercedes Alonso‐Sanz, María José Rebollo Espinosa et al. · Journal of Clinical Microbiology Open access May 2001 54
31 Rationale and Design of the AFFIRM-AHF Trial: A Randomised, Double-Blind, Placebo-Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron-Deficient Patients Admitted for Acute Heart Failure Piotr P. Ponikowski et al. · European Journal of Heart Failure Open access Dec 2019 53
32 Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome Maria Dall’Era, Victoria Levesque, Neil Solomons et al. · Lupus Science & Medicine Open access May 2015 53
33 Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients Csaba Pal Kovesdy, Christopher G. Rowan, Ansgar Conrad et al. · Kidney International Reports Open access 29 Oct 2018 52
34 4-Fluorinated l -lysine analogs as selective i-NOS inhibitors: methodology for introducing fluorine into the lysine side chain E. Ann Hallinan, Steven W. Kramer, Stephen C. Houdek et al. · Organic & Biomolecular Chemistry 2003 50
35 A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study Ann Willman Silk et al. · Cancer Immunology Immunotherapy Open access 29 Nov 2022 49
36 A Programmatic Approach to Patient Blood Management – Reducing Transfusions and Improving Patient Outcomes Shannon L. Farmer, Kevin M. Trentino, Axel Hofmann et al. · The Open Anesthesiology Journal Open access 27 Aug 2015 46
37 Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia Peter Geisser, José Banké-Bochita · Arzneimittelforschung 21 Dec 2011 45
38 Traceless Solid-Phase Synthesis of 1,2,4-Triazoles Using a Novel Amine Resin Scott D. Larsen, Brian A. DiPaolo · Organic Letters 22 Sep 2001 45
39 Do self-report and medical record comorbidity data predict longitudinal functional capacity and quality of life health outcomes similarly? Adesuwa B. Olomu, William D. Corser, Manfred Stommel et al. · BMC Health Services Research Open access 14 Nov 2012 45
40 Comparative Absorption and Bioavailability of Various Chemical Forms of Zinc in Humans: A Narrative Review Prasad P. Devarshi, Qingqing Mao, Ryan W. Grant et al. · Nutrients ReviewOpen access 11 Dec 2024 44
41 Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex Michael S. South, Brenda L. Case, Rhonda S. Wood et al. · Bioorganic & Medicinal Chemistry Letters Open access 9 Jun 2003 42
42 Dermal, Subdermal, and Systemic Concentrations of Granisetron by Iontophoretic Delivery Ayyappa Chaturvedula, Dipty P. Joshi, Carter Anderson et al. · Pharmaceutical Research Aug 2005 41
43 Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study Pablo E. Pérgola, David M. Spiegel, Suzette Warren et al. · American Journal of Nephrology Open access 2017 40
44 Pharmacokinetics and Metabolism of a COX-2 Inhibitor, Valdecoxib, in Mice Ji Y. Zhang, Josh J. Yuan, Yue-Fen Wang et al. · Drug Metabolism and Disposition 18 Mar 2003 40
45 The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation Nahid Tabibzadeh, Angelo Karaboyas, Bruce Robinson et al. · Nephrology Dialysis Transplantation Open access 9 Jul 2020 39
46 Intravenous iron and erythropoiesis‐stimulating agents in haemodialysis: A systematic review and meta‐analysis Simon D. Roger, Martin Tio, Hyeong Cheon Park et al. · Nephrology ReviewOpen access 11 Oct 2016 39
47 Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy Michael Hedenus, Torbjörn Karlsson, Heinz Ludwig et al. · Medical Oncology Open access 5 Nov 2014 39
48 Bioerodible injectable poly(ortho ester) for tetracycline controlled delivery to periodontal pockets: Preliminary trial in humans Khadija Schwach‐Abdellaoui, Pierre‐Jean Loup, N Vivien-Castioni et al. · AAPS PharmSci Open access Dec 2002 36
49 Protection against vascular endothelial dysfunction by polyphenols in sea buckthorn berries in rats with hyperlipidemia Fang Yang, Yourui Suo, Dongli Chen et al. · BioScience Trends Open access 2016 34
50 Development and validation of a liquid chromatography–tandem mass spectrometric assay for Eplerenone and its hydrolyzed metabolite in human plasma Ji Y. Zhang, Douglas M. Fast, Alan P. Breau · Journal of Chromatography B 25 Mar 2003 31

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.